share_log

Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10

Benzinga Real-time News ·  Jan 27, 2023 10:46

Morgan Stanley analyst Michael Ulz maintains Xilio Therapeutics (NASDAQ:XLO) with a Overweight and lowers the price target from $20 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment